window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

NDA

  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China

    Adneuris Therapeutics has granted Zhejiang Conba Pharmaceutical exclusive rights to [...]

    July 15, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Compass reports second positive Phase 3 trial of psilocybin therapy for treatment-resistant depression

    Compass Pathways has reported positive six-month results from its second [...]

    July 8, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Abivax reports positive Phase 3 maintenance data for obefazimod in ulcerative colitis

    Abivax has reported positive topline results from Part 2 of [...]

    July 3, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Poolbeg Pharma trial targets cytokine release syndrome in multiple myeloma
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development
  • FairJourney Bio builds switch to activate IL-12 in tumours
    Categories: Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Germfree and Nuvai add AI monitoring to IV compounding
    Categories: Biotech & Pharma Business, Digital & Data, Drug Delivery & Formulation, Manufacturing & Supply Chain, Medical devices
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top